During its 3Q17 earnings release on October 18, 2017, Abbott Laboratories (ABT) provided an updated guidance for fiscal 2017 and 4Q17. Abbott raised its fiscal 2017 guidance, and ABT stock gained ~1.3% that same day.The Vanguard Dividend Appreciation ETF (VIG) also registered a rise in its price. ABT stock makes up ~2.6% of VIG’s total holdings.
Interested in ABT?
				Don't miss the next report.
			
				Receive e-mail alerts for new research on ABT

Success! 
			You are now receiving e-mail alerts for new  research. A temporary password for your new Market Realist account has been sent to your e-mail address.
		
Success! 
 has been added to your Ticker Alerts.
		
Success! 
 has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.
		Abbott raised the midpoint and narrowed the range of its adjusted earnings per share guidance for fiscal 2017. The range is estimated to be $2.48–$2.50 per share, compared with the previous estimate of $2.43–$2.53.Abbott forecasts its comparable operational sales growth in fiscal 2017 to be in the mid-single digits, which would be consistent with its previous guidance. Foreign currency exchange is expected to have a positive impact of ~0.50% on Abbott’s total sales growth in fiscal 2017.Abbott maintained its R&D (research and development), SG&A (selling, general, and administrative), and gross margin guidance at 7.5%, 30%, and 59.5%, respectively, of total sales.According to Wall Street analysts, peers Thermo Fisher Scientific (TMO), Boston Scientific (BSX), and Becton, Dickinson, and Company (BDX) have fiscal 2017 sales growth estimates of ~$20.6 billion, ~$9 billion, and ~$12.8 billion, respectively.In 4Q17, Abbott expects its adjusted EPS (earnings per share) to be $0.72–$0.74. The comparable operational sales growth is estimated to be in the mid-to-high single digits. Foreign exchange fluctuations are expected to have a positive impact of ~2%.Nutrition segment sales are expected to grow in the low-single digits, whereas Diagnostics sales are estimated to grow by mid-single digits in 4Q17. Abbott’s Medical Devices segment is expected to register mid-to-high single-digit sales growth, while the Established Pharmaceuticals segment’s sales are expected to continue to grow by double digits.Quote data by Xignite